We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Iron wins 3 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Likely helps
11 of 15 studies with measurable effects showed benefit.
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
18-45mg elemental iron for deficiency (varies by severity)
On empty stomach if tolerated, Away from tea, coffee, dairy
Ferrous bisglycinate (gentle, well-absorbed) or iron protein succinylate
Investigational — NO approved dose. Phase-2 trials used once-weekly subcutaneous injection with stepwise escalation up to 4.8-6.0 mg maintenance. There is no approved regimen; do not self-dose an unapproved drug.
once-weekly
Once-weekly subcutaneous injection (investigational only)
2-4 weeks
4-8 weeks
4-12 weeks
Progressive over 24-46 weeks
By 48 weeks
By 16-46 weeks
Especially during dose escalation
Daily oral iron supplementation during pregnancy
The Cochrane database of systematic reviews (2024) · Meta analysis · n=48971
There is probably little to no difference in maternal death (2 versus 4 events, RR 0.57, 95% CI 0.12 to 2.69; 3 trials, 14,060 women; moderate-certainty evidence).
The Prevalence of Anemia among Pregnant Women in China: A Systematic Review and Meta-Analysis
Nutrients (2024) · Meta analysis · n=722
The results showed that the prevalence of anemia, ID, and IDA among pregnant women in China were 30.7% (95% CI: 26.6%, 34.7%), 45.6% (95% CI: 37.0%, 54.2%), and 17.3% (95% CI: 13.9%, 20.7%), respectively.
Treatment for women with postpartum iron deficiency anaemia
The Cochrane database of systematic reviews (2024) · Meta analysis · n=572
Intravenous iron versus oral iron supplementation The evidence is very uncertain about the effect of intravenous iron on mortality (risk ratio (RR) 2.95, 95% confidence interval (CI) 0.12 to 71.96; P = 0.51; I² = not applicable; 3 RCTs; 1 event; 572 women; very low-certainty evidence).
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.
N Engl J Med (2024) · Rct · n=293
48-week phase-2, double-blind, randomized, placebo-controlled trial in 293 adults with biopsy-confirmed MASH and fibrosis stage F1-F3, once-weekly subcutaneous survodutide 2.4/4.8/6.0 mg vs placebo with a 24-week rapid-escalation then 24-week maintenance design
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.
Lancet Diabetes Endocrinol (2024) · Rct · n=387
Phase-2, double-blind, randomized, placebo-controlled dose-finding trial in 387 adults with obesity (BMI ≥27) across 43 centres in 12 countries, once-weekly subcutaneous survodutide 0.6-4.8 mg vs placebo for 46 weeks
Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial.
Diabetologia (2024) · Rct · n=413
Phase-2, multicentre, double-blind, randomized, placebo-controlled dose-response trial in 413 adults with type 2 diabetes, once-weekly subcutaneous survodutide across six dose groups vs placebo, with an open-label semaglutide reference arm
Based on meta-analyses showing hemoglobin improvements of 2.01-5.30 g/dL in iron deficient populations. Higher doses show diminishing returns with increased GI side effects. Effectiveness varies significantly by baseline iron status and form used.
AI-estimated from published studies. Interpret as directional guidance.
Iron has a higher evidence score (9/10 vs 5.5/10) and wins in 3 of 3 categories.
No known interactions between Iron and Survodutide have been documented in our database. However, always consult a healthcare provider before combining supplements.